Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qishenyiqi Dripping Pill in Coronary Microvascular Disease
NCT06699420Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronary microvascular disease (CMD) comparing Qishenyiqi Dripping Pill with Placebo (2 arms). Primary endpoint: Coronary Flow Reserve at 1 year. Started Nov 2023; status: recruiting.
02
Drugs
qishen yiqi dripping pills
03
Conditions
coronary microvascular disease (CMD)
Beyond the preview
Go deeper on NCT06699420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06699420.